Hamlet BioPharma AB (Hamlet), a clinical-stage biopharmaceutical company advancing targeted oncological and other therapies, today announces that its wholly owned subsidiary Alpha1H BC AB (A1HB) its collaborator Linnane Pharma AB (Linnane) and Hamlet have signed a non-binding Letter of Intent (LoI) with an undisclosed company specializing in uro-oncology based in northern Germany. The purpose is to outline terms and conditions for the completion of development and for global commercialization of Alpha 1H in the field of bladder cancer.

Alpha 1H is being developed by Hamlet and Linnane as a therapy for bladder cancer, a field where there is a great unmet medical need for novel therapies. Initially focusing on neoadjuvant therapy, the program represents a differentiated clinical positioning in a significant global indication.

Hamlet has previously communicated that Alpha 1H has received Fast Track designation from the U.S. Food and Drug Administration (FDA) and clearance from the FDA to proceed with a pivotal Phase III study. The project is thus entering a registration-enabling stage with a defined regulatory pathway.

The execution of the terms and conditions for a commercial agreement is subject to satisfactory completion of due diligence by all parties to the LoI and further negotiation and preparation of the definitive agreement containing the full terms and conditions. Each party agrees to act in good faith to complete its due diligence and to negotiate, execute and complete the definitive agreement after the execution of this agreement.

All parties are aware of and accept that Hamlet is in discussions with other parties about a possible partnership concerning Alpha 1H in the field and that such discussions will continue in parallel with the discussions between the parties.

Hamlet and Linnane are supported in the process by PharmaVentures, an international advisory firm specializing in pharmaceutical partnering and licensing transactions. The purpose of the engagement is to ensure that any potential agreement is structured in line with international market standards.

"The dialogue with our potential partner has been very constructive and forward-looking. At this stage, the focus is on optimal completion of clinical development, manufacturing scale-up and establishing the right commercial framework to plan market access. This intended co-development would position us to deliver long-term value to patients, healthcare systems and shareholders, subject to successful study outcomes and market approval", comments Catharina Svanborg, Chairman of the Board.

For more information please contact:

Catharina Svanborg, Chairman of the Board, Hamlet BioPharma, +46-709 42 65 49

[email protected]

Jakob Testad, CEO, Hamlet BioPharma, +46-708 48  42 10

[email protected]